Category Archives: Investor

The Story About Wes Edens

Freedom checks are run by the government and are not federal as they sound. A federal law known as Statute 26-F enables the free tax investment to take place. The investments enable more than 550 energy-related firms to sell their generous contributions either quarterly or by monthly checks by investors. The firms referred to as master limited partnerships play a crucial role in natural gas and oil industries. For the firms to qualify for free checks, they must give to the investors 90cents of every dollar they make. Transportation of fuel by pipelines and drilling of new oil wells is done by Wes Edens operate refineries. Some of the shareholders receive up to 160000 dollars every quarterly. The earnings are referred to as distributions by most Wes Edens refineries firms.

Investors pay a small tax on capital gains if they sell their shares. Thus the federal charges do not apply to the Wes Edens either their shareholders. The firms are exempted from paying tax since the government want to encourage energy production. President Nixon saw the need to come up with a law that would help people to invest in natural gas and refiners. This law was focused that united states would be independent in energy production. The bill was a reward to the domestic investors in the energy sector. A freedom check encompasses opportunities such as real estate investment trust that provide another tax-free option. Shareholders receive nine-tenths of the income. Americans can start buying shares $50 – $100 in spare cash. This investment calls for firms to engage in production, processing, storage and transportation of natural gas in the United States primarily focused on oil and gas industries.

This strategy was embraced when importation of oil from the Middle East to the United States decreased. This was followed by the increase of oil and gas here in the united states thus the government exempted tax for the industries. This would ensure the United States is sufficient in the production and supplying of oil and gas products. Companies have generated massive figures regarding profit, and they will contribute $ 34.6 billion as freedom cheeks to savvy investors in over 12 coming months. There may be dramatically rising of the firms that invest in energy since freedom checks trade like any other stock. Currently, 580 firms contribute to freedoms checks by paying monthly or quarterly payments. For a firm to be am a member, the firm should pay 90% of its income to investors. If a firm decides to sell Wes Edens firm, any profit earned. The tax is gain by the lower capital gains.

To know more click: here.

Tony Petrello takes philanthropy to Nabors Industries

Although Tony Petrello is known more for his work in the oil and gas drilling industry, it is his contributions to philanthropic foundations that has been gaining a lot of attention in recent times. There is focus on the things that he is doing in helping the needy people in the community. Tony Petrello who lives in Texas is one of the committed persons who want to impart a culture of helping one another in the business sector. Through the business that he leads known as Nabors industries, he is committed to helping the people who are in need of support, for the past few years, he has been contributing to various initiatives which are supposed to change the lives of needy people. He has a special focus on children as well as victims of disasters.

Tony Petrello and the Nabors Industries participate in the rescue mission that ensued when Hurricane Harvey hit Houston, there was an urgent appeal for humanitarian support. Petrello being a generous man sent all willing employees of the company on a paid leave so that they could engage in rescue missions. In addition, the employees and their CEO contributed $300,000 that went to the relief fund for the victims of the hurricane.

Tony has shown that a business should not only be seen when it is selling its products to the people; it should be seen when there us needs in the community. A good relationship with the community is one of the best ways of endearing a company to the people. All the billions made by business such as Nabors Industries should have an impact on the community and should not all go compensation plans.

Tony Petrello has created a culture in Nabors Industries where workers are now receptive to philanthropic work. By seeing the contributions that their leader is making, they emulate. Today, Nabors is offering yearly contributions to various relief organizations in the country. The workers of this company have also been engaging in their philanthropic drives to support the communities that are in need. Tony Petrello gives a lot from his wealth, and he is bringing the same things to Nabors Industries.

To know more click: here.

Proteostasis Under Attack By Sahm Adrangi For Drug Breakthrough Statements

Sahm Adrangi is always on the lookout for companies that are worthwhile investments in various markets, including the medical market. That being said, Sahm is also wary of companies that are potentially problematic and when he finds one, he lets everyone know. Kerrisdale Capital, Sahm Adrangi’s investment management firm, recently released a review of the biotech company, Proteostasis. This review is not the good kind, as Sahm Adrangi calls into question whether or not this company is fabricating their medical results.

Proteostasis recently made an announcement that they have created a new drug that can combat cystic fibrosis, claiming this drug can greatly improve lung performance for those afflicted with the illness. Sahm Adrangi is no stranger to taking on biotech companies, having combated some of the biggest in the world without hesitation, and Proteostasis is no different. The data that has been put forth by Protestais has been analyzed by Kerrisdale Capital, and much of it is not promising in regards to their new “breakthrough” drug.

The testing that this biotech company has done is not yet complete, especially since their first run using the drug only comprised of four different patients. This is hardly a big enough sample size to determine whether or not a drug is effective for people. For Proteostasis to make these claims so prematurely, the data for the effectiveness of their drug is actually skewed. For all Proteostasis knows, their drug acted as a placebo for their patients.

Sahm Adrangi is concerned that this company’s claims have actually been falsified because of the pressure against them for creating a product that is successful. Not only is their data largely incomplete and devoid of test results, but Proteostasis stands to lose the majority of their company value should this drug not work out. With all of the problems looking into this biotech company, Sahm is warning people of their claims and investors to stay clear. Since Kerrisdale’s report released, Proteostasis’s company stock value has decreased by 16 percent, amounting to tens of millions of dollars.

Eric Leftkofsky and His Many Successes

Eric Leftkofsky is the co-founder of the company Tempus. Tempus is a company that specializes in data-enabled precision medicine. Eric also co-founded Groupon, but Tempus has a personal meaning to him due to his wifes condition.

Erics wife was diagnosed with breast cancer. That is when he found out about the mess that is data collection and digital technology. There was so much data about patients and their treatments, but there was no effective way to gather that information and put it to use. Now in steps Tempus. They waned to revolutionize the way that cancer care was delivered. And while they have discovered ways to analyze a patients clinical and molecular data, it didn’t come easy. Problems are bound to happen when you are talking about such a huge project, and initially there was a few of them. Ensuring that this information was affordable and accessible was problematic from the start. Plus, making sure that this sensitive information about patients was stored. Luckily, these hurdles were solved with Tempus creating its own software to ensure that a physicians notes could be transformed into structured data. Other procedures, such as human genome sequencing, used to be expensive, and unattainable by the average working person. Fortunately, companies like Tempus are helping drive the price down from the $100 million it was in 2003 to the $5000 it is today, plus it is expected to continue to lower. Tempus continues to make strides in the data-enabled precision medicine field, and hopes to help doctors pair patients with treatment more accurately.

Leftkofsky was born in Southfield, Michigan in 1969. He attended, and graduated from the University of Michigan before partaking in the dot-com revolution. Tempus headquarters is located in Chicago, which is where he spends most of his time. He has held several teaching positions over the years at different business and management schools, and now teaches as an adjunct professor at the University of Chicago’s Booth School of Business.

Is Bitcoin Good For 2018? Paul Mampilly Says ‘No’

Paul Mampilly, a former Managing Director for one of Wall Street’s top hedge funds offers a lot of investment advice through his newsletters and articles at Banyan Hill Publishing, and one area he talks about there is cryptocurrency. He said in one article that he wasn’t fully aware of just what a phenomena Bitcoin would become in 2017, but while it had a great uptick this year, it’s something he says investors should avoid now. What Mampilly says is that Bitcoin is becoming popular, but so much so that its overall value is going to be hurt in the long run. It’s reached a certain level that has made it overpriced and as a result, it’s become like a bubble the same way that the housing market was in 2008.

Paul Mampilly is usually correct when he makes a prediction in the stock market. He foresaw both the dot-com crash and the housing crisis in his time, and he also decided to buy Facebook and Netflix stocks before they soared and became big companies. He got his degree in economics and finance back in 1991 after graduating from Montclair State University, and then he took a job as a research assistant at Deutsche Bank. After serving tenures at Deutsche Bank, ING, Sears, Banker’s Trust and a private Swiss bank, Mampilly founded Capuchin Consulting and later took a job as Managing Director for Kinetics International Fund. Here he made so much money for investors that Barron’s featured the hedge fund as one of the top ones on Wall Street, and the firm’s assets under management grew from $6 billion to $25 billion in months. Two years after joining Kinetics International Fund, Paul Mampilly won the Templeton Foundation’s award for investing $50 million in profitable stocks during the recession and making $88 million.

Paul Mampilly stayed on Wall Street until a couple years ago when he decided his job really wasn’t helping average Americans invest the way it should. He had plenty of experience and market inside knowledge, but he wanted to share it with people in a way that was more accessible than most regular publications provided. So he joined Banyan Hill Publishing in 2016 and started writing about big stocks and how people could buy them with no brokers in “Profits Unlimited.” Most people who read this newsletter were skeptical at first, but upon seeing that his advice really was true, Paul Mampilly gained 60,000 subscribers in just one month after releasing it.

Paul Mampilly’s Social Media: